Briefing

Featured article

Prasad’s shock FDA return reignites regulatory uncertainty

Also in this section

News in Numbers

Latest News

Latest Deals

08/20/2025 15:50:33
  • Home | Big biopharma takes on the ADC challenge
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Datwyler Company Insight
  • Datwyler
  • Cytiva
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Molnar-Institute Company Insight
  • Molnar-Institute
  • In Depth
  • Big biopharma takes on the ADC challenge
  • Targeting energy expenditure: the next wave of obesity drugs
  • Synthetic rescue: Insmed explores a new frontier in genetic therapeutics
  • A new way forward in ovarian cancer: why synthetic iMSCs could change the paradigm
  • New US-EU trade deal on tariffs ends pharma’s geopolitical immunity
  • Uncertainty around tariffs is a disincentive for pharma onshoring in the US
  • Uncertainty remains over FDA ruling on CGT trial samples
  • Cell and gene therapies on correction course but not sinking
  • Syngene Company Insight
  • INOSIM
  • Listings
  • Events
  • Excellence Awards
  • Buyer's Guides
  • Next issue
08/20/2025 00:00:00